BEONE MEDICINES USA
PharmaBEONE MEDICINES USA is a pharmaceutical company focused on Oncology, Gastroenterology, Dermatology. Key products include BRUKINSA.
FDA Novel Drug Designations
(2019)See 1 novel approval →
BEONE MEDICINES USA at a Glance
- Growing R&D activity with 26 trials in last 2 years
BEONE MEDICINES USA's Key Drugs
BEONE MEDICINES USA's core commercial portfolio centers on BRUKINSA, BEQALZI, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
BEONE MEDICINES USA's Recent FDA Approvals
BEONE MEDICINES USA secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
BEONE MEDICINES USA's Therapeutic Areas
BEONE MEDICINES USA's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BEONE MEDICINES USA's Top Competitors
BEONE MEDICINES USA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PF PRISM CV, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BEONE MEDICINES USA Pipeline Snapshot
BEONE MEDICINES USA has 42 active clinical programs from ClinicalTrials.gov — 11 Phase 3, 3 Phase 2 and 28 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BRUKINSA leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/10 completed
- • Speed: N/A months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges